期刊文献+

丹酚酸对ADP诱导的血小板聚集的影响 被引量:2

Inhibitory Effects of Salvianolic Acids on ADP-induced Platelet Aggregation
下载PDF
导出
摘要 目的研究丹酚酸(salvianolic acid,SA)及其代谢物对腺苷-5'二磷酸(adenosine-5-diphosphate,ADP)诱导的血小板聚集的影响,为寻找到高效低毒的抗血栓药物提供依据。方法取健康雄性SD大鼠动脉血浆,以药物替格瑞洛为阳性对照,ADP为诱导剂,考察SA对血小板聚集的体外作用,用比浊法测定血小板聚集率,结果用IC_(50)表示。结果 SA表现出中等的体外抑制ADP诱导血小板聚集的作用,IC_(50)值0.3~0.9 mmol/L。结论丹酚酸具有温和的抑制体外ADP诱导血小板聚集的作用,且有很好的研究价值。 Objective To investigate the role of salvianolic acids(SA)and the metabolites on ADP-induced platelet aggregation for the development of antithrombotic drugs with high efficiency and low toxicity.Methods Arterial plasma was collected from healthy male SD rats.Taking Ticagrelor as positive control,the in vitro role of salvianolic acids on ADP-induced platelet aggregation was examined by turbidimetry and the results were expressed by IC_(50).Results Salvianolic acids displayed moderate inhibitory effect on ADP-induced platelet aggregation with IC_(50) values ranging from 0.3 to 0.9 mmol/L.Conclusion Salvianolic acids have gentle inhibitory effect on ADP-induced platelet aggregation in vitro,indicating superior research value.
作者 李红 张云 付丙月 鲜婧 张相军 王金虎 石海英 LI Hong;ZHANG Yun;FU Bing-yue;XIAN Jing;ZHANG Xiang-jun;WANG Jin-hu;SHI Hai-ying(Shandong Academy of Pharmaceutical Sciences,Jinan 250101,China)
出处 《食品与药品》 CAS 2021年第1期52-55,共4页 Food and Drug
关键词 丹酚酸 血小板聚集 ADP salvianolic acid platelet aggregation ADP
  • 相关文献

参考文献1

二级参考文献37

  • 1Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin[J]. Journal of the American College of Cardiology . 2008 (3)
  • 2Wei C. Lau,Lucy A. Waskell,Paul B. Watkins,Charlene J. Neer,Kevin Horowitz,Amy S. Hopp,Alan R. Tait,David G.M. Carville,Kirk E. Guyer,Eric R. Bates.Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction[J]. Circulation: Journal of the American Heart Association . 2003 (1)
  • 3Mega Jessica L,Close Sandra L,Wiviott Stephen D,Shen Lei,Walker Joseph R,Simon Tabassome,Antman Elliott M,Braunwald Eugene,Sabatine Marc S.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. The Lancet . 2010
  • 4Wallentin Lars,Becker Richard C,Budaj Andrzej,Cannon Christopher P,Emanuelsson H?kan,Held Claes,Horrow Jay,Husted Steen,James Stefan,Katus Hugo,Mahaffey Kenneth W,Scirica Benjamin M,Skene Allan,Steg Philippe Gabriel,Storey Robert F,Harringt.Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England Quarterly . 2009
  • 5Shamir R Mehta,Salim Yusuf,Ron JG Peters,Michel E Bertrand,Basil S Lewis,Madhu K Natarajan,Klas Malmberg,Hans-Jürgen Rupprecht,Feng Zhao,Susan Chrolavicius,Ingrid Copland,Keith AA Fox.??Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study(J)The Lancet . 2001 (9281)
  • 6Renli Teng,Stuart Oliver,Martin A. Hayes.Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects. DRUG METABOLISM AND DISPOSITION . 2010
  • 7Taubert Dirk,von Beckerath Nicolas,Grimberg Gundula,Lazar Andreas,Jung Norma,Goeser Tobias,Kastrati Adnan,Sch?mig Albert,Sch?mig Edgar.Impact of P-glycoprotein on clopidogrel absorption. Clinical Pharmacokinetics . 2006
  • 8Yusuf S,Zhao F,Mehta S R,Chrolavicius S,Tognoni G,Fox K K.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The New England Quarterly . 2001
  • 9Angiolillo Dominick J,Fernandez-Ortiz Antonio,Bernardo Esther,Ramírez Celia,Sabaté Manel,Jimenez-Quevedo Pilar,Hernández Rosana,Moreno Raul,Escaned Javier,Alfonso Fernando,Ba?uelos Camino,Costa Marco A,Bass Theodore A,Macaya Carlos.Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes . 2005
  • 10J. T.BRANDT,S. L.CLOSE,S. J.ITURRIA,C. D.PAYNE,N. A.FARID,C. S.ERNEST,D. R.LACHNO,D.SALAZAR,K. J.WINTERS.??Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel(J)Journal of Thrombosis and Haemostasis . 2007 (12)

共引文献3

同被引文献25

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部